Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca/Bristol's Diabetes Drug Onglyza Cleared

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca hints that drug could be priced lower than Merck's blockbuster Januvia.
Advertisement

Related Content

For Bristol, Onglyza Disappoints And Health Care Reform Takes A Toll
For BMS, Onglyza Disappoints And Health Care Reform Takes A Toll
Bristol/AstraZeneca Roll Out Onglyza Post-Market Cardio Study
BMS Buys Into Promising Neuropathic Pain Market Via Allergan Deal
Bristol Myers-Squibb/AstraZeneca's Onglyza Officially Cleared For Europe
CV Safety Gets Diabetes Drugs Approved, Not Sold, AstraZeneca Exec Notes
AstraZeneca/Bristol's Diabetes Drug Priced On Par With First-In-Class Januvia
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Will Sanofi's Lantus Survive Cancer Scare? Studies Suggest a Worrisome Link
Will Sanofi's Lantus Survive Cancer Scare? Studies Suggest a Worrisome Link

Topics

Advertisement
UsernamePublicRestriction

Register

PS069775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel